ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates

ProQR (PRQR) reported a wider-than-expected loss of $0.12 per share for the quarter ended September 2025, missing the Zacks Consensus Estimate of a $0.10 loss by 20%. The Dutch drugmaker also posted revenues of $3.37 million, significantly missing estimates by 60.57% and declining from $4.22 million year-over-year. This marks the fourth consecutive quarter ProQR has failed to meet both EPS and revenue consensus estimates, contributing to its 10.2% year-to-date stock decline against a rising S&P 500, and resulting in a Zacks Rank #3 (Hold) rating.

Analysis

ProQR (PRQR) reported a wider-than-expected Q3 loss of $0.12 per share, missing the Zacks Consensus Estimate of a $0.10 loss by 20%. Concurrently, revenues of $3.37 million significantly underperformed expectations, missing by 60.57% and representing a decline from $4.22 million year-over-year. This marks the fourth consecutive quarter the Dutch drugmaker has failed to surpass both EPS and revenue consensus estimates.

The persistent underperformance has seen PRQR shares lose 10.2% year-to-date, sharply contrasting with the S&P 500's 15.6% gain over the same period. The sustainability of immediate price movement hinges on management's commentary during the upcoming earnings call, particularly regarding future earnings expectations. The stock currently holds a Zacks Rank #3 (Hold), suggesting an in-line market performance in the near term.

Despite ProQR's individual struggles, the broader Medical - Biomedical and Genetics industry, to which it belongs, is positioned favorably, ranking in the top 41% of Zacks industries. For the coming quarter, consensus estimates project a loss of -$0.05 per share on $8.55 million in revenues, with the full fiscal year anticipating a -$0.40 loss on $20.46 million in revenues. These estimates will be critical to monitor for revisions post-earnings call.

Key Decisions for Investors

• Consider monitoring management commentary closely for future guidance and pipeline updates, as past performance indicates a lack of execution against estimates.
• Evaluate the impact of potential negative estimate revisions following the earnings call, given the consistent misses and the stock's current Zacks Rank #3 (Hold).
• Assess ProQR's performance relative to its strong industry backdrop; while the sector is robust, the company's individual fundamentals show significant weakness.